No Data
Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $22
Y-mAbs Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 79.15% HC Wainwright & Co. $21 → $22 Maintains Buy 03/06/2024 79.15% HC Wainwright & Co. $21 →
Bank of America Securities Sticks to Its Hold Rating for Y-Mabs Therapeutics (YMAB)
Maintaining Buy Rating on Y-Mabs Therapeutics: A Financial and Clinical Catalyst Outlook
Express News | Y-mAbs Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $22 From $21